Y. Tahirovic

发表

Enantiomeric propanolamines as selective N-methyl-D-aspartate 2B receptor antagonists.

Matthew T. Geballe, J. Snyder, J. McNamara, 2008, Journal of medicinal chemistry.

A GluN2B-selective inhibitor of NMDA receptor function with enhanced potency at acidic pH and oral bioavailability for clinical use

Polina, R. Dingledine, D. Liotta, 2021 .

A Glutamate N-Methyl-d-Aspartate (NMDA) Receptor Subunit 2B–Selective Inhibitor of NMDA Receptor Function with Enhanced Potency at Acidic pH and Oral Bioavailability for Clinical Use

R. Dingledine, D. Liotta, S. Traynelis, 2021, The Journal of Pharmacology and Experimental Therapeutics.

Structural elements of a pH-sensitive inhibitor binding site in NMDA receptors

M. Regan, D. Liotta, Zongjian Zhu, 2019, Nature Communications.

Synthesis and Evaluation of Novel Tetrahydronaphthyridine CXCR4 Antagonists with Improved Drug-like Profiles.

Eric J Miller, Eric J. Miller, C. A. Derdeyn, 2022, Journal of medicinal chemistry.

Synthesis and SAR of 1,2,3,4-Tetrahydroisoquinoline-Based CXCR4 Antagonists.

Eric J Miller, D. Liotta, C. Sum, 2018, ACS medicinal chemistry letters.

Discovery of Tetrahydroisoquinoline-Containing CXCR4 Antagonists with Improved in Vitro ADMET Properties.

Eric J Miller, D. Liotta, C. Sum, 2018, Journal of medicinal chemistry.

Amino-Heterocycle Tetrahydroisoquinoline CXCR4 Antagonists with Improved ADME Profiles via Late-Stage Buchwald Couplings.

Eric J Miller, D. Liotta, C. Sum, 2021, ACS medicinal chemistry letters.

Small molecule and peptide-based CXCR4 modulators as therapeutic agents. A patent review for the period from 2010 to 2018

Eric J Miller, Eric J. Miller, D. Liotta, 2019, Expert opinion on therapeutic patents.

Synthesis of Novel Tetrahydroisoquinoline CXCR4 Antagonists with Rigidified Side-Chains.

Eric J Miller, D. Liotta, C. Sum, 2018, ACS medicinal chemistry letters.

Discovery of N-Alkyl Piperazine Side Chain Based CXCR4 Antagonists with Improved Drug-like Properties.

Eric J Miller, Eric J. Miller, D. Liotta, 2018, ACS medicinal chemistry letters.

The synthesis, antimicrobial activity studies, and molecular property predictions of novel benzothiazole-2-thione derivatives

Y. Tahirovic, S. N. Biltekin, B. Berk, 2017 .

CCR5 receptor antagonists in preclinical to phase II clinical development for treatment of HIV

D. Liotta, L. Wilson, Y. Tahirovic, 2016, Expert opinion on investigational drugs.

An NMDAR positive and negative allosteric modulator series share a binding site and are interconverted by methyl groups

D. Liotta, S. Traynelis, P. Burger, 2018, eLife.

Context-Dependent GluN2B-Selective Inhibitors of NMDA Receptor Function Are Neuroprotective with Minimal Side Effects

J. Snyder, D. Liotta, S. Traynelis, 2015, Neuron.

Novel GluN2B-Selective NMDA Receptor Negative Allosteric Modulator Possesses Intrinsic Analgesic Properties and Enhances Analgesia of Morphine in a Rodent Tail Flick Pain Model

R. Dingledine, M. Regan, S. Traynelis, 2023, ACS chemical neuroscience.

Design, Synthesis, and Pharmacological Evaluation of Second-Generation Tetrahydroisoquinoline-Based CXCR4 Antagonists with Favorable ADME Properties.

D. Liotta, C. Sum, L. Wilson, 2018, Journal of medicinal chemistry.

Synthesis, structural activity-relationships, and biological evaluation of novel amide-based allosteric binding site antagonists in NR1A/NR2B N-methyl-D-aspartate receptors.

R. Dingledine, D. Liotta, M. Yepes, 2009, Bioorganic & medicinal chemistry.

A novel class of negative allosteric modulators of NMDA receptor function.

D. Liotta, S. Traynelis, Hongjie Yuan, 2015, Bioorganic & medicinal chemistry letters.

A GluN2B-selective inhibitor of NMDA receptor function with enhanced potency at acidic pH and oral bioavailability for clinical use

Polina, R. Dingledine, D. Liotta, 2021 .